Innova Captab

Innova Captab LT Debt/Equity

The Long-Term Debt to Equity Ratio of Innova Captab (INNOVACAP.NS) as of Oct 28, 2026 is 0.20. In the previous year, Long-Term Debt to Equity Ratio was 0.25 — a change of -22.43% (lower).

LT Debt/Equity

0.20

YoY

-22.43%

Last updated:

Long-Term Debt to Equity Ratio of Innova Captab is 2026 0.20 . Long-Term Debt to Equity Ratio of Innova Captab was 2025 0.25 . It decreases by -22.43% lower compared to the previous year.

The Innova Captab LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2020
0.15 INR
Jan 1, 2021
0.04 INR
Jan 1, 2022
0.32 INR
Jan 1, 2023
1.01 INR
Jan 1, 2024
0.25 INR
Jan 1, 2025
0.25 INR
Jan 1, 2026
0.20 INR
The Innova Captab LT Debt/Equity history
YEARLT Debt/EquityYoY
0.20-22.43%
0.25+1.31%
0.25-75.18%
1.01+212.72%
0.32+679.30%
0.04-72.79%
0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

Long-Term Debt to Equity Ratio of Innova Captab is 0.20 in 2026.

Long-Term Debt to Equity Ratio of Innova Captab changed from 0.25 to 0.20, representing a -22.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Innova Captab since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Innova Captab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Innova Captab

All Key Metrics — Innova Captab